EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Hospital Miguel Servet
Zaragoza, EspañaHospital Miguel Servet -ko ikertzaileekin lankidetzan egindako argitalpenak (10)
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
2018
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2016
2015
-
Chemotherapy-associated anemia in patients with lung cancer: An epidemiological, retrospective and multicenter study
Future Oncology, Vol. 11, Núm. 11, pp. 1665-1674
-
Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel
Future Oncology, Vol. 11, Núm. 2, pp. 267-277
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2006
-
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study
British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802